Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.

doi:10.1182/blood.2023021105

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.

Blood - 11 Apr 2024

Bourgeois Wallace, Cutler Jevon A, Aubrey Brandon J, Wenge Daniela V, Perner Florian, Martucci Cynthia, Henrich Jill A, Klega Kelly, Nowak Radosław P, Donovan Katherine A, Boileau Meaghan, Wen Yanhe, Hatton Charlie, Apazidis Athina A, Olsen Sarah Naomi, Kirmani Nadia, Pikman Yana, Pollard Jessica A, Perry Jennifer A, Sperling Adam S, Ebert Benjamin L, McGeehan Gerard M, Crompton Brian D, Fischer Eric S, Armstrong Scott A

Abstract excerpt

ABSTRACT: Small molecules that target the menin-KMT2A protein-protein interaction (menin inhibitors) have recently entered clinical trials in lysine methyltransferase 2A (KMT2A or MLL1)-rearranged (KMT2A-r) and nucleophosmin-mutant (NPM1c) acute myeloid leukemia (AML) and are demonstrating encouraging results. However, rationally chosen combination therapy is needed to improve responses and prevent resistance. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lenalidomide

Share to Leukemia, Myeloid, Acute

Share to Morpholines

Share to Mutation

Share to Myeloid-Lymphoid Leukemia Protein

Share to Phthalimides

Share to Transcription Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 38096371
DOI: 10.1182/blood.2023021105
PMCID: PMC11033588

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.PMID 38096371Read ↗

Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemiasSemantic proximity Read ↗

Menin Inhibitors: A New Era of Targeted Therapies in Acute Myeloid Leukemia.Semantic proximity Read ↗

Pharmacological Characterization of JNJ-75276617, a Menin-KMT2A Inhibitor, As Targeted Treatment for KMT2A-Altered and NPM1-Mutant Acute LeukemiaSemantic proximity Read ↗

Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 MutationSemantic proximity Read ↗

Menin inhibitors in KMT2A-rearranged and NPM1-mutated acute leukemia: A scoping review of safety and efficacySemantic proximity Read ↗

Therapeutic Targeting of the Menin–KMT2A InteractionSemantic proximity Read ↗

Emerging drug profile: menin inhibitors in NPM1-mutated and KM2A-rearranged acute myeloid leukemia.Semantic proximity Read ↗

Menin inhibitors in the treatment of acute myeloid leukemiaSemantic proximity Read ↗

Menin Inhibitors in Acute Myeloid Leukemia-What Does the Future Hold?Semantic proximity Read ↗

Ziftomenib: First Approval.Semantic proximity Read ↗

Menin inhibitors in KMT2A-rearranged leukemia: Mechanistic insights, clinical trial progress, and potential of combination therapiesSemantic proximity Read ↗

Combined Menin and XPO1 inhibition drive synergistic antileukemic activity in <i>KMT2A</i> r and <i>NPM1</i> -m AMLSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.